Current Management of Juvenile Myelomonocytic Leukemia and the Impact of RAS Mutations
Pediatric Drugs, 04/25/2012Yoshida N et al.
Cumulative evidence suggests that RAS mutations can be related to favorable clinical outcomes, and hematopoietic stem cell transplantation (HSCT) may not have to be a mandatory therapeutic option for a portion of patients with this mutation, although a consensus regarding genotype–based management has not yet been achieved. Further efforts toward identifying which patients who will do well without HSCT are required.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.